Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2018 August;66(4) > Minerva Cardioangiologica 2018 August;66(4):411-21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  STEMI: CURRENT KNOWLEDGE AND FUTURE PERSPECTIVES 

Minerva Cardioangiologica 2018 August;66(4):411-21

DOI: 10.23736/S0026-4725.18.04619-4

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Parenteral antithrombotic therapy during primary percutaneous coronary intervention

Federico FORTUNI 1, 2 , Marco FERLINI 2, Sergio LEONARDI 2

1 University of Pavia, Pavia, Italy; 2 IRCCS Policlinico San Matteo Foundation, Pavia, Italy


PDF


Acute myocardial infarction (AMI) is a major cause of morbidity, mortality and disability worldwide. ST-segment elevation myocardial infarction (STEMI) accounts for 25-40% of AMI presentations. Arterial thrombosis due to atherosclerotic plaque rupture with formation of an occlusive thrombus is the main cause of STEMI. Platelets and coagulation factors are the two principal elements involved in this process. The main goal of STEMI treatment is the early reperfusion. Prompt primary percutaneous coronary intervention (pPCI) together with an appropriate antithrombotic therapy are the treatment of choice in this setting. In this chapter, we provide an overview of currently available parenteral antithrombotic therapies used in patients with STEMI undergoing pPCI.


KEY WORDS: Fibrinolytic agents - Infusions, parenteral - ST elevation myocardial infarction - Therapeutics

top of page